-
ABOUT USAffiliated to SSY Group Limited, Hebei Guangxiang Technology Co., Ltd., is a high-tech enterprise specializing in drug research and technology development.
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the synergy between “industry, academia, research and application” based on multi-disciplinary integration and multi-directional combination.
-
SUBORDINATEThe group has decided to establish research institutes in its subsidiaries, Hebei Ghuangxiang Drug Research Institute, Jiangsu Best Medical Material Research Institute, and Hebei Hanlin Biological Research Institute.
-
RECRUITWe actively establish a joint talent cultivation mechanism between schools and enterprises, and currently have over 500 high-level talents in various fields such as drug research, analysis, and clinical practice.
-
CONTACTWe will continue to strengthen innovation-driven development, vigorously promote the integration of production and research, constantly improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs.
Shijiazhuang No.4 Pharmaceutical has been awarded the national-level Manufacturing Single Champion title.
Category:
Time：2022-11-28
Recently, the Ministry of Industry and Information Technology of China and the China Federation of Industrial Economics announced the seventh batch of Manufacturing Single-Champion Enterprises (Products), and Shijiazhuang Sihua Pharmaceutical Co., Ltd. was recognized as a Manufacturing Single-Champion.
Recently, the Ministry of Industry and Information Technology of China and the China Federation of Industrial Economics announced the seventh batch of Manufacturing Single-Champion Enterprises (Products), and Shijiazhuang Sihua Pharmaceutical Co., Ltd. was recognized as a Manufacturing Single-Champion enterprise.
A “Manufacturing Single-Item Champion” refers to enterprises and products that have long been focused on specific niche segments of the manufacturing market, possess internationally leading production technologies or processes, and rank among the world’s top in terms of market share for their respective single-item products. Cultivating these Manufacturing Single-Item Champions is an important component of promoting high-quality development in the manufacturing sector. Since 2016, the Ministry of Industry and Information Technology has conducted seven rounds of selection for Manufacturing Single-Item Champion enterprises (and products).
The “Single-Item Champion” is hailed as the “pearl” atop the crown of manufacturing—a crucial benchmark for measuring a company’s market share in a specific product category and its level of technological innovation. As a leading enterprise in China’s injection production, R&D, and export sectors, Shijiazhuang No.4 Pharmaceutical leverages its own industrial strengths by aligning its industrial chain with the innovation chain and enhancing its value chain through the industrial chain. The company actively develops and applies new, iteratively improved products that boast high added value and promising market prospects. It has also proposed and participated in drafting over 90 relevant quality and technical standards as well as patents. Moreover, capitalizing on the leading demonstration effect of its intravenous solution industry, the company has powerfully driven the industrial application and large-scale production of soft-packaged intravenous solutions. In recent years, Shijiazhuang No.4 Pharmaceutical’s sales and production of soft-bag intravenous solutions have maintained rapid growth, capturing nearly half of the domestic market and exporting to more than 90 countries and regions worldwide, thereby significantly boosting the transformative upgrade of the company’s flagship products.
“Single-item champions” cannot do without the support of core technologies. Shijiazhuang No.4 Pharmaceutical has closely focused on the main theme of transformation and upgrading, as well as improving quality and efficiency. By attracting and introducing high-level innovative talents, the company continues to promote the extension, supplementation, and strengthening of its industrial chain, and drives innovation in core technology products. With a dedicated effort to overcome “bottleneck” key technologies, the company’s project, “Establishment and Application of a Quality Control Technology System for Soft-Packaged Large Volume Infusions,” won the First Prize for Scientific and Technological Progress in Hebei Province. The industrial chain structure—including generic drugs, innovative drugs, specialty APIs, and pharmaceutical packaging materials—has been continuously optimized and upgraded. In the first 10 months of this year, Shijiazhuang No.4 Pharmaceutical ranked among the top in the country in terms of the number of approved and filed specialty generic drugs, continually empowering the company’s high-quality development. Su Xuejun, Chairman of Shijiazhuang No.4 Pharmaceutical, stated that the company must seize the new opportunities presented by Shijiazhuang’s initiative to achieve breakthroughs in the biopharmaceutical industry, leverage the leading role of scientific and technological innovation, accelerate product innovation and the commercialization of research findings, and continuously cultivate and create more “single-item champion products.”
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Mobile site
E code
Business license